Free Trial

Azenta Q3 2023 Earnings Report

Azenta logo
$50.43 +0.93 (+1.88%)
(As of 12/20/2024 05:45 PM ET)

Azenta EPS Results

Actual EPS
$0.13
Consensus EPS
-$0.03
Beat/Miss
Beat by +$0.16
One Year Ago EPS
$0.12

Azenta Revenue Results

Actual Revenue
$165.95 million
Expected Revenue
$153.42 million
Beat/Miss
Beat by +$12.53 million
YoY Revenue Growth
+25.00%

Azenta Announcement Details

Quarter
Q3 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Azenta Earnings Headlines

Azenta (NASDAQ:AZTA) Upgraded by Stephens to "Overweight" Rating
Stephens & Co. Upgrades Azenta (AZTA)
Rare "crisis signal" triggers for third time in U.S. market
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
See More Azenta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azenta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azenta and other key companies, straight to your email.

About Azenta

Azenta (NASDAQ:AZTA) provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

View Azenta Profile

More Earnings Resources from MarketBeat

Upcoming Earnings